KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Leases (2016 - 2025)

Rigel Pharmaceuticals has reported Current Leases over the past 14 years, most recently at $614000.0 for Q4 2025.

  • Quarterly results put Current Leases at $614000.0 for Q4 2025, up 115.44% from a year ago — trailing twelve months through Dec 2025 was $614000.0 (up 115.44% YoY), and the annual figure for FY2025 was $614000.0, up 115.44%.
  • Current Leases for Q4 2025 was $614000.0 at Rigel Pharmaceuticals, up from $594000.0 in the prior quarter.
  • Over the last five years, Current Leases for RIGL hit a ceiling of $9.9 million in Q4 2021 and a floor of $285000.0 in Q4 2024.
  • Median Current Leases over the past 5 years was $682500.0 (2023), compared with a mean of $3.1 million.
  • Biggest five-year swings in Current Leases: crashed 94.59% in 2023 and later surged 115.44% in 2025.
  • Rigel Pharmaceuticals' Current Leases stood at $9.9 million in 2021, then plummeted by 88.55% to $1.1 million in 2022, then crashed by 38.92% to $692000.0 in 2023, then tumbled by 58.82% to $285000.0 in 2024, then surged by 115.44% to $614000.0 in 2025.
  • The last three reported values for Current Leases were $614000.0 (Q4 2025), $594000.0 (Q3 2025), and $517000.0 (Q2 2025) per Business Quant data.